Darren Cowzer
@CowzerDarren
Followers
360
Following
302
Media
18
Statuses
98
Medical oncologist @Matercancer via @MSK_DeptOfMed and @UCDMedicine
Dublin, IRE
Joined November 2018
RT @OncJournal: This retrospective study provides a comprehensive analysis of the clinical and genomic predictors of response to immune che….
0
3
0
RT @MSK_DeptOfMed: Starting at 11:30 a.m. PST: @ASCO #GI25 poster sessions! Stop by the West Hall for #pancreaticcancer and #biliarytractca….
0
8
0
RT @MSKLibrary: Featured today by @MSKLibrary: Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with….
0
3
0
RT @STARTDublinPh1: Delighted to announce Goodman Fellowship opportunity in Phase 1 Oncology for medical oncology trainees in Ireland @Mate….
0
10
0
RT @MSKLibrary: Featured today by @MSKLibrary: A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Ge….
0
2
0
RT @cancertrials_ie: It was clear to see the enormous impact of Pat Smullen's legacy at @curraghrace this Saturday. The funds raised by Pa….
0
12
0
Great to have mentors and colleagues @ImaneDika Geoff Ku from @MSK_DeptOfMed here presenting in Ireland @CancerGathering
0
3
25
RT @JCOPO_ASCO: 🩸Data from @CowzerDarren, @HardingJJMD, et al. showing how NGS of #cfDNA in HCC represents an alternative to tissue-based p….
0
1
0
RT @MLaszkowskaMD: Excited to share our latest work in @jitcancer! @DavidFaleckMD @SteveMaronMD @CowzerDarren @YJanjigianMD @MSKCancerCente….
0
4
0
RT @JCOPO_ASCO: 👀 Check out what’s popular this week in #JCOPO:. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With….
0
1
0
RT @ArndtVogel: First-line regorafenib with nivo & FOLFOX in GEJ/GC in the USA: a single-arm, single-centre, phase 2 trial.@TheLancetOncol….
0
16
0
RT @KarynAGoodman: Great to see the team @MSKCancerCenter building on the CALGB 80803 PET-directed therapy trial with the addition of immun….
0
5
0
Proud to see this in print. Only possible with the brilliant mentorship of @HardingJJMD and support of all STGI team @MSK_DeptOfMed @YJanjigianMD @GABOUALFA @EileenMOReilly & Co @JCOPO_ASCO.
Congratulations to @CowzerDarren and team @MskccCMO, @MFBerger1, @DSolit, @Gaboualfa, and @HardingJJMD! Their paper on tumor mutation profiling of circulating cell-free DNA in people with #livercancer was published today in @JCOPO_ASCO. Read it here:
0
13
60
RT @TumorBoardTues: 🌍 <1 hour until TONIGHT’S cross-continental #TumorBoardTuesday. 🪚@KlempnerSam @CowzerDarren join to cut deep into #Gast….
0
3
0
RT @TumorBoardTues: 🪚CLAUDIN 18.2 has been a topic of discussion, & there’s fresh & emerging treatments for #GastricCancer. 🇮🇪Join @Klempne….
0
21
0
RT @TheLancetOncol: NOW OF: A US single-arm, single-centre, ph 2 trial assesses the safety and activity of regorafenib in combination with….
0
18
0
RT @shahid_pmc: Congratulations @geosullivanc and team. Atezolizumab for Advanced Alveolar Soft Part Sarcoma | NEJM
nejm.org
Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported....
0
1
0
RT @TumorBoardTues: 🇮🇪Case prep is underway for this week’s #TumorBoardTuesday!. 👨🏻⚕️Join @CentralParkWMD @ferguskeane2 08.29.23 8pm ET, t….
0
25
0
RT @BookOncology: Thanks to everyone that voted!.We are pleased to announce that our next book is This Living and Immortal Thing by @aduffy….
0
10
0